Abstract

Neurofibromatosis type 1 (NF1) is a autosomal-dominant multi-systemic disorder derives from a mutation in the 17q11.2 gene (1). The incidence is 1 in 2500-3500 live births and the prevalence is 1 in 4000-5000. The characteristic features of this disease are café-au-lait spots, freckling in intertriginous regions and Lisch nodules. Although NF1 is considered as a tumor predisposing sydrome over cenral and peripheral nervous system tumors it presents wide nonneoplastic conditions including pigmental abnormalities (are café-au-lait spots, freckling in intertriginous regions and Lisch nodules), skeleton abnormalities and neurobehavioral abnormalities ( learning disorder, attention deficit disorder, hyperactivity disorder). The initial definition of endocrine disorders, the complication of NF1, goes back to the 1970s. We discussed the prececious puberty detected in the monitoring of NF1 male patient, who is 8 and a half years old, with optic pathway glioma in this paper.

Keywords: nörofibromatozis tip 1, optik gliom, puberte prekoks, GnRH analoğu

References

  1. Fountain JW, Wallace MR, Brereton AM, O’Connell P, White RL, Rich DC, et al. Physical mapping of the von Recklinghausen neurofibromatosis region on chromosome 17. Am J Hum Genet 1989;44:58-67.
  2. Cnossen MH, Stam EN, Cooiman LC, Simonsz HJ, Stroink H, Oranje AP, et al. Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics 1997;100:667-70.
  3. Saxena KM. Endocrine manifestations of neurofibromatosis in children. Am J Dis Child 1970;120:265-71.
  4. Laue L, Comite F, Hench K, Loriaux DL, Cutler GB Jr, Pescovitz OH. Precocious puberty associated with neurofibromatosis and optic gliomas. Treatment with luteinizing hormone releasing hormone analogue. Am J Dis Child 1985;139:1097-100.
  5. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1-6.
  6. Hirabaru K, Matsuo M. Neurological comorbidity in children with neurofibromatosis type 1. Pediatr Int 2018;60:70-5.
  7. Habiby R, Silverman B, Listernick R, Charrow J. Precocious puberty in children with neurofibromatosis type 1. J Pediatr1995;126:364-7.
  8. PescovitzOH, Comite F, Cassorla F, DwyerAJ, Poth MA, Sperling MA et al: True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. J Clin Endocrinol Metab 1984; 58: 857–61.
  9. Kotwal N, Yanamandra U, Menon AS, Nair V: Central precocious puberty due to hypothalamic hamartoma in a six-month-old infant girl. Indian J Endocrinol Metab 2012; 16: 627–30.
  10. Brauner R, Malandry F, Rappaport R, Zucker JM, Kalifa C, Pierre-Kahn A et al: Growth and endocrine disorders in optic glioma. Eur J Pediatr 1990; 149: 825–28.
  11. Listernick R, Charrow J, Greenwald M, MetsM: The national history of optic path way tumors in children with neurofibromatosis type1: a longitudinal study. J Pediatr 1994; 125: 63–66.
  12. Stein DT: Southwestern Internal Medicine Conference. New developments in the diagnosis and treatment of sexual precocity. Am J Med Sci 1992; 303: 53–71.
  13. Zacharin M: Precocious puberty in two children with neurofibromatosis type 1 in the absence of optic chiasmal glioma. J Pediatr 1997; 130: 155–57.
  14. Rubin JB, Gutmann DH: Neurofibromatosis type 1 – a model for nervous system tumour formation? Nat Rev Cancer 2005; 5: 557–64.
  15. Hegedus B, Yeh TH, Lee da Y, Emnett RJ, Li J, Gutmann DH: Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum Mol Genet 2008; 17: 2956–66
  16. Marshall M: Interactions between Ras and Raf: key regulatory protein in cellular transformation. Mol Reprod Dev 1995; 42: 493–99.

How to cite

1.
Coşkun ZN. Central Prec0cious Puberty in Neurofibromatosis Type 1 With Optic Glioma. Turk J Pediatr Dis [Internet]. 2020 Jan. 27 [cited 2025 Aug. 23];14(1):89-91. Available from: https://turkjpediatrdis.org/article/view/730